Investment
Features
FeesSafety
Academy
More
Pluang+

S&P 500 rises 30.6% in first 20 months of Trump's second term, nearing first term gains.

Market News
15 Oct 2026
James Brumley
View Source
Neutral
S&P 500 rises 30.6% in first 20 months of Trump's second term, nearing first term gains.

The S&P 500 index has increased by 30.6% during the first 20 months of Donald Trump's second presidential term, slightly surpassing the 28.5% gain recorded in the same period of his first term. This comparison is significant for investors as it provides insight into market performance trends under Trump's leadership, especially ahead of the upcoming midterm elections. Understanding these trends can help investors anticipate potential market movements influenced by political events.

The Vanguard ETF Warren Buffett endorses for young investors is the story's subject, with Pluang market data providing context. As of Oct 16, 2026 01:21 WIB, out of 150 priced US stocks tradable on Pluang, 111 rose and 39 fell. Notable movers include Macy's Inc (M) up 6.53% at USD 24.16 with a typical hold time of 58 days, Nike Inc (NKE) up 6.52% at USD 37.60 with a typical hold time of 155 days and a Pluang order activity of 54% Sell / 46% Buy, and Lucid Group Inc (LCID) up 5.78% at USD 3.48 with a typical hold time of 45 days and 97% Sell / 3% Buy order activity.

More News

Copper explorers in British Columbia use electrical surveys to identify promising drill targets amid rising copper prices.

Copper explorers in British Columbia use electrical surveys to identify promising drill targets amid rising copper prices.

Copper exploration in British Columbia is increasingly relying on induced polarization (IP) geophysical surveys, which measure electrical chargeability and resistivity in rocks to identify sulphide mineralization associated with copper deposits. Gold...

Market News
Bullish
32 minutes ago
Citigroup raises Krystal Biotech price target on Vyjuvek sales and promising KB113 trial results

Citigroup raises Krystal Biotech price target on Vyjuvek sales and promising KB113 trial results

Citigroup increased its price target for Krystal Biotech to $416 from $386, citing strong Q2 revenue of $119.2 million from its approved product Vyjuvek and encouraging early clinical data for KB113, a treatment for basal cell carcinomas in Gorlin sy...

Analyst Insights
Bullish
1 hour ago
Bank7 beats Q3 earnings estimates but revenue dips; merger with Century Financial set to close soon

Bank7 beats Q3 earnings estimates but revenue dips; merger with Century Financial set to close soon

Bank7 Corp. reported Q3 2026 earnings of $1.06 per share, slightly beating analyst estimates, while revenue of $23.37 million fell short and declined year-over-year. Despite lower revenue and earnings compared to last year, the bank continues to grow...

Company Fundamentals
Neutral
1 hour ago
Scotiabank raises Targa Resources price target to $319, citing strong momentum and a $1.25 dividend.

Scotiabank raises Targa Resources price target to $319, citing strong momentum and a $1.25 dividend.

Scotiabank increased its price target for Targa Resources to $319 from $314, indicating a potential 12.7% upside from the current share price of around $283. Targa Resources, a key player in the midstream energy sector, is recognized as a top momentu...

Analyst Insights
Bullish
2 hours ago
Ericsson beats Q3 earnings estimates on strong mobile network demand despite margin concerns for 2027

Ericsson beats Q3 earnings estimates on strong mobile network demand despite margin concerns for 2027

Ericsson reported better-than-expected Q3 earnings with EPS of $0.18 and revenue of $5.91 billion, driven by strong demand in its mobile network segment. The Networks division showed 9% organic growth and a gross margin above guidance, but overall op...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App